Quick Answer
Generic semaglutide (the active ingredient in Ozempic) is now available in India for as low as Rs 750 per weekly injection — approximately Rs 3,400 per month — after the patent expired in March 2026. Indian companies including Sun Pharma and Dr. Reddy's have launched versions at up to 80% lower cost than branded Ozempic.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
The biggest barrier to GLP-1 therapy for most Indian patients has always been cost. Branded Ozempic and Wegovy from Novo Nordisk have historically cost Rs 20,000 to Rs 30,000 per month in India — far beyond the reach of most patients who need it. That changed dramatically when the patent for semaglutide expired in India in March 2026. In the weeks that followed, at least five major Indian pharmaceutical companies launched generic versions of the drug at prices up to 80% lower than the original branded product.
What Has Changed in 2026
Semaglutide — the active molecule in Ozempic and Wegovy — lost patent protection in India in March 2026. Within days of the patent expiry, multiple Indian manufacturers began selling their own versions. Sun Pharmaceutical launched a generic semaglutide injection for as low as Rs 750 per weekly dose, which works out to approximately Rs 3,400 per month at the starting dose. Dr. Reddy's Laboratories launched an oral semaglutide formulation in India in April 2026, signalling movement toward more patient-friendly delivery formats. Other manufacturers including Natco, Cipla, Glenmark, and Biocon are also now in the market.
By June 2026, over 40 Indian pharmaceutical companies are expected to have launched more than 50 generic semaglutide products. India is rapidly becoming one of the most competitive markets in the world for affordable GLP-1 medications.
Who Can Now Access GLP-1 Treatment
Before the generic launch, GLP-1 therapy in India was primarily limited to upper-income urban patients who could afford branded medications or who had very comprehensive insurance coverage. At Rs 3,400 to Rs 6,000 per month for generic semaglutide, the population that can now practically access these medications has expanded enormously.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
GLP-1 medications are medically indicated for type 2 diabetes management and for weight loss in patients with obesity. In India, the obesity threshold is a BMI of 27.5 — lower than the Western cutoff of 30 — because Indian body types carry metabolic risk at lower BMIs. India has over 100 million people with type 2 diabetes and many millions more with obesity or metabolic syndrome. Even a fraction of this population accessing treatment represents a meaningful shift in how India manages its metabolic disease burden.
Is Generic Semaglutide as Effective as Branded Ozempic
This is the most common question patients are asking. The active molecule is identical — semaglutide is semaglutide, regardless of which company manufactures it. Indian manufacturers including Sun Pharma, Dr. Reddy's, Cipla, and Natco are among the most respected pharmaceutical companies in the world, producing to international GMP standards with Indian regulatory approval.
Patients should, however, purchase only from licensed pharmacies and verify the source of their medication. Reports of counterfeit and unregulated GLP-1 products sold online and through informal channels have surfaced. Buying from unknown sources carries serious safety risks — these are potent medications with real side effects when used incorrectly.
How to Start GLP-1 Therapy Safely
GLP-1 medications must be started at a low dose and titrated upward gradually. The standard starting dose for semaglutide is 0.25 mg per week, held for 4 weeks before any dose increase. This slow titration is essential — it minimises nausea and vomiting in the early weeks, which are the most common side effects. Most patients can complete the adjustment period with manageable discomfort if the dose escalation is done correctly under medical supervision.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
In major clinical trials, average weight loss on semaglutide was 12 to 15% of total body weight over 68 weeks. For a patient weighing 90 kg, that represents 11 to 14 kg of sustained weight loss, which can substantially reduce the risk of diabetes complications, joint pain, fatty liver disease, and cardiovascular events. GLP-1 therapy is not appropriate for everyone — patients with a personal or family history of medullary thyroid cancer or pancreatitis must discuss risks with a specialist before starting.
Oral vs. Injectable — A New Choice for Indian Patients
The launch of oral semaglutide by Dr. Reddy's in April 2026 is particularly significant. Many Indian patients are reluctant to use injectable medications due to needle anxiety or practical difficulties with self-injection. The oral tablet format offers similar metabolic benefits with weekly dosing and no needle required. However, oral semaglutide requires specific administration — taken on an empty stomach with only a small amount of water, 30 minutes before food — and the absorbed dose differs from the injectable version. A GLP-1 specialist can advise which format suits your individual situation and starting health status.
MySurgery connects Indian patients with experienced GLP-1 specialists in Delhi, Mumbai, Bangalore, Chennai, Hyderabad, and Pune who can help you start treatment correctly, titrate your dose safely, and identify the most cost-effective generic option now available in your city.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. CNBC — https://www.cnbc.com/2026/03/23/novo-nordisk-cheap-weight-loss-drugs-india-generic-ozempic-wegovy-semaglutide.html 2. PharmaBiz — https://www.pharmabiz.com/NewsDetails.aspx?aid=185867&sid=1 3. India Briefing — https://www.india-briefing.com/news/ozempic-generic-glp1-drug-manufacturing-race-in-india-43676.html/
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.